Kuros starts Phase II clinical trial in bone regeneration
Kuros reaches key milestone in its collaboration with Baxter
Kuros, a biotechnology company that develops novel biologics and biomaterials for localised therapy, announced that it has started a Phase II clinical trial in tibial plateau fractures as part of its collaboration with Baxter in hard and soft tissue repair. The Phase II clinical trial will be conducted by Kuros and aims to evaluate the safety and efficacy of the product.
Kuros' product in this indication utilises Kuros' technology for binding proprietary biologics within Baxter's fibrin-based biomatrix, TISSEEL Fibrin Sealant, to create a bioactive bone graft substitute for in-situ healing of long bone fractures. The product is injected directly at the fracture site, where it forms a solid fibrin composite that matches the shape of the fracture. According to the company, the product promotes bone growth through the release upon cellular demand of a modified version of a naturally occurring bone-forming molecule bound to the fibrin matrix.
Kuros entered into a major licence & collaboration agreement with Baxter Healthcare in 2005. The collaboration covers the development of a number of biological combination products targeted at certain skin and orthopaedic indications.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Artificial intelligence could improve therapy for lymphoma
Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
Yale Researchers Discover New Potential Asthma Therapeutic Targets Related to Parasites and Insects
Protagen Expands Cooperation with Bayer HealthCare
Emergent BioSolutions Announces Appointment of Ronald Richard to the Board of Directors

Deadly combination: new direct trigger for cell death discovered - Understanding the basic mechanisms that lead to cell death is essential for the development of therapies for cancer and other diseases

Bayer: Supervisory Board extends CEO Werner Baumann’s - Contract until the end of April 2024

Restoring vision by gene therapy - Latest scientific findings give hope for people with incurable retinal degeneration
Pantec Biosolutions receives ISO 13485 certification
Stora Enso awarded as Finland’s most startup-friendly company
Genetic screening before embryo transfer fails to improve the chance of a baby
